Samsung Biologics said Wednesday it plans to select and support biotech companies to join “C-Lab Outside” in Songdo in partnership with Eli Lilly.
The company unveiled an operating roadmap for C-Lab Outside, which is scheduled to be established next year, at the “Bio Korea 2026” event.
Lee Sang-myeong, executive director in charge of CDO development at Samsung Biologics, said Songdo International City is expected to grow into the world’s largest bio cluster by 2030 and called it an ideal location for open innovation with infrastructure spanning the value chain.
Under the collaboration, the companies plan to jointly select and support up to 30 biotechs capable of developing next-generation therapies.
C-Lab Outside is set to be completed in July next year at Samsung Biologics’ second bio campus in Songdo, Incheon. The five-story facility will have a total floor area of about 12,000 square meters.
Recruitment will begin in the fourth quarter of this year, before the center is completed, and will target early-stage startups at Series B or below. Companies that already have partnerships with global conglomerates will be excluded. Tenancy will be two years, extendable to a maximum of four years.
Selection and incubation will be carried out jointly with Lilly’s innovation program, Lilly Gateway Labs (LGL).
Samsung Biologics said it is also expanding support for South Korea’s biotech ecosystem through biotech investment, seminars and efforts to localize raw and subsidiary materials. A company official said it plans to broaden support, including creating an industry development fund worth 25 billion won.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.